Figure 7.

miR-455-3p Suppresses HSF1 Expression in Hepatic Fibrosis Tissues

(A) Immunohistochemical staining of α-SMA in liver tissues from mice transfected with the AC and ago-miR-455-3p with CCl₄-, BDL-, and HFD-induced liver fibrosis. (B) The quantification of the α-SMA-positive area in untreated mice and mice transfected with the AC and ago-miR-455-3p with CCl₄-, BDL-, and HFD-induced liver fibrosis. (C) The protein levels of α-SMA, Collagen-I, and TIMP-1 in liver tissues from untreated mice and mice transfected with the AC and ago-miR-455-3p with CCl₄-, BDL-, and HFD-induced liver fibrosis were examined by western blotting. (D) The expression level of HSF1 in untreated mice and mice transfected with AC and ago-miR-455-3p with CCl₄-, BDL-, and HFD-induced liver fibrosis was examined by quantitative real-time PCR. (E) The protein levels of HSF1, Hsp47, TGF-β, and Smad4 in liver tissues from untreated mice and mice transfected with AC and ago-miR-455-3p with CCl₄-, BDL-, and HFD-induced liver fibrosis were examined by western blotting. Graph represents mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001.